{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:28:09Z","timestamp":1793287689668,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V115C-095"],"award-info":[{"award-number":["V115C-095"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V114B-015"],"award-info":[{"award-number":["V114B-015"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V115B-008"],"award-info":[{"award-number":["V115B-008"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V114C-039"],"award-info":[{"award-number":["V114C-039"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["113-2314-B-075 -057 -MY3"],"award-info":[{"award-number":["113-2314-B-075 -057 -MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["110-2314-B-075-016 MY3"],"award-info":[{"award-number":["110-2314-B-075-016 MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.tjog.2025.11.019","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T19:47:33Z","timestamp":1769629653000},"page":"15-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mirvetuximab soravtansine-Gynx (MIRV) for treating platinum-resistant recurrent ovarian cancer"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6048-8541","authenticated-orcid":false,"given":"Peng-Hui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che-Wei","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu-Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hsun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjog.2025.11.019_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104230","article-title":"Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with FR\u03b1 positive expression: a systematic review and meta-analysis","volume":"194","author":"Wang","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.tjog.2025.11.019_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252211927","article-title":"Folate receptor alpha-a secret weapon in ovarian cancer treatment?","volume":"25","author":"Bukowski","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.tjog.2025.11.019_bib3","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3390\/ijms25021046","article-title":"Folate receptor alpha-a novel approach to cancer therapy","volume":"25","author":"Gonzalez","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.tjog.2025.11.019_bib4","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/JCMA.0000000000001310","article-title":"A challenge for treating patients with extensive-stage small cell lung cancers, particularly for those with liver metastases","volume":"88","author":"Wang","year":"2025","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2025.11.019_bib5","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/JCMA.0000000000001293","article-title":"Optimizing outcomes for the patients with extensive-stage small-cell lung cancer","volume":"88","author":"Wang","year":"2025","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2025.11.019_bib6","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.tjog.2024.03.034","article-title":"Endometrial cancer: part II. Multimodality treatment of uterine high-grade serous carcinoma (clinical course I)","volume":"64","author":"Chang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.11.019_bib7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.tjog.2025.04.001","article-title":"Endometrial cancer: part II. Multimodality treatment of uterine high-grade serous carcinoma (clinical course II)","volume":"64","author":"Chang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.11.019_bib8","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.tjog.2022.09.001","article-title":"Endometrial cancer: part I. Basic concept","volume":"61","author":"Wang","year":"2022","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.11.019_bib9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.tjog.2024.03.033","article-title":"Complex tumor microenvironment of endometrial cancer","volume":"64","author":"Yang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.11.019_bib10","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/JCMA.0000000000001283","article-title":"Genomic insights for triple-negative breast cancer patients in Taiwan","volume":"88","author":"Wang","year":"2025","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2025.11.019_bib11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.tjog.2024.11.006","article-title":"Current genetic test for ovarian cancer","volume":"64","author":"Yang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.11.019_bib12","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.tjog.2024.09.005","article-title":"Antibody-drug conjugates (ADCs) may be a big breakthrough in gynecologic cancer treatment (I)","volume":"63","author":"Wang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.11.019_bib13","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.tjog.2025.09.018","article-title":"Targeted biomarkers of antibody-drug conjugates (ADCs)","volume":"64","author":"Wang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.11.019_bib14","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.tjog.2025.09.003","article-title":"Antibody-drug conjugates (ADCs) may be a big breakthrough in gynecologic cancer treatment (III): understanding of ADC","volume":"64","author":"Wang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.11.019_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/JCMA.0000000000001317","article-title":"Programmed death-ligand 1 (PD-L1) upregulation is associated with poor prognosis in patients with epithelial ovarian cancer","volume":"89","author":"Liu","year":"2026","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2025.11.019_bib16","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.tjog.2025.09.019","article-title":"Completeness of interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer","volume":"64","author":"Wang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.11.019_bib17","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/JCMA.0000000000001253","article-title":"Is C3c structure useful as biomarkers for epithelial ovarian cancer?","volume":"88","author":"Wang","year":"2025","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2025.11.019_bib18","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/ijgo.70292","article-title":"Targeting the ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) as a potential therapeutic strategy to overcome anti-VEGF resistance in endometrial cancer","volume":"171","author":"Liu","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2025.11.019_bib19","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/JCMA.0000000000001069","article-title":"Minimally invasive approach is preferred for clinical stage 1 endometrioid-type endometrial cancer","volume":"87","author":"Wang","year":"2024","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2025.11.019_bib20","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/JCMA.0000000000001077","article-title":"CA 125 for surgico-pathological stage 1 endometrial cancer","volume":"87","author":"Wang","year":"2024","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2025.11.019_bib21","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.tjog.2024.03.002","article-title":"Immunohistochemical staining for cytology-based cervical cancer screening","volume":"63","author":"Chang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.11.019_bib22","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tjog.2024.04.005","article-title":"Cervical cancer: part I human papilloma virus vaccination in Taiwan","volume":"63","author":"Yang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.11.019_bib23","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.tjog.2025.04.004","article-title":"Cervical cancer in Taiwan","volume":"64","author":"Yang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.11.019_bib24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ijgo.15609","article-title":"Bevacizumab is associated with a higher gastrointestinal\/genitourinary fistula or perforation risk in cervical cancer patients undergoing pelvic radiotherapy","volume":"167","author":"Yang","year":"2024","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2025.11.019_bib25","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.tjog.2024.07.013","article-title":"Besides the front-line maintenance therapy, is any positive impact of poly (ADP-ribose) polymerase (PARP) inhibitors on recurrent high-grade ovarian cancer?","volume":"63","author":"Li","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.11.019_bib26","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.tjog.2024.09.002","article-title":"Neoadjuvant chemotherapy is associated with worse prognosis in patients with advanced-stage epithelial ovarian cancer: is it real?","volume":"63","author":"Li","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.11.019_bib27","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.tjog.2024.09.003","article-title":"Primary cytoreductive surgery or interval cytoreductive surgery","volume":"63","author":"Li","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"issue":"Suppl 1","key":"10.1016\/j.tjog.2025.11.019_bib28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ijgo.70033","article-title":"Worldwide barriers of optimal surgical care provision in advanced ovarian cancer","volume":"171","author":"Varghese","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2025.11.019_bib29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tjog.2023.11.005","article-title":"Front-line chemoimmunotherapy for treating epithelial ovarian cancer: part II promising results of phase 2 study of paclitaxel-carboplatin-oregovomab regimen","volume":"63","author":"Yang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.11.019_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tjog.2024.11.003","article-title":"Primary cytoreductive surgery for advanced epithelial ovarian cancer patients is still popular in gynecologic oncologists in Korea and Taiwan, particularly apparent in Taiwan","volume":"64","author":"Wang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"issue":"Suppl 1","key":"10.1016\/j.tjog.2025.11.019_bib31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ijgo.70282","article-title":"Cancer of the ovary, fallopian tube, and peritoneum: 2025 update","volume":"171","author":"Renz","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2025.11.019_bib32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ijgo.15391","article-title":"Rates of genetic consultation in high-grade serous ovarian cancer patients in the era of PARP inhibitor therapy: a population-based study","volume":"166","author":"Brent","year":"2024","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.tjog.2025.11.019_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104893","article-title":"Effectiveness and safety of PARP inhibitors in ovarian cancer: an umbrella review of systematic reviews and meta-analyses","volume":"215","author":"Tzang","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.tjog.2025.11.019_bib34","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"PAOLA-1\/ENGOT-ov25 investigators. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.tjog.2025.11.019_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.04.024","article-title":"Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer","volume":"189","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.tjog.2025.11.019_bib36","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"ICON7 trial investigators. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tjog.2025.11.019_bib37","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/IGC.0000000000001258","article-title":"Angiogenesis inhibitors for the treatment of ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials","volume":"28","author":"Wang","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.tjog.2025.11.019_bib38","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13048-025-01864-3","article-title":"Vascular endothelial generating factor pathway in ovarian cancer","volume":"18","author":"Zhao","year":"2025","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.tjog.2025.11.019_bib39","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/JCMA.0000000000001296","article-title":"Management of hormone receptor-positive\/human epidermal growth factor receptor 2-negative breast cancer patients: first-line therapy","volume":"88","author":"Wang","year":"2025","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2025.11.019_bib40","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/JCMA.0000000000001282","article-title":"Outcomes of everolimus-treated HR+\/HER2- breast cancer","volume":"88","author":"Wang","year":"2025","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2025.11.019_bib41","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.tjog.2025.05.012","article-title":"The decision for adjuvant therapy for early-stage high-risk endometrial cancer is in dilemma","volume":"64","author":"Wang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.11.019_bib42","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.tjog.2025.03.001","article-title":"The frontiers in gynecologic cancer management: exploring the new hope to manage women with endometrial cancer by immunochemotherapy","volume":"64","author":"Wang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.11.019_bib43","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/JCMA.0000000000001255","article-title":"Genomic insights for neuroendocrine prostate cancer","volume":"88","author":"Wang","year":"2025","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2025.11.019_bib44","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.41648","article-title":"PARP inhibitor maintenance after first-line chemotherapy in advanced-stage epithelial ovarian cancer: a systematic review and meta-analysis","volume":"8","author":"Petousis","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.tjog.2025.11.019_bib45","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tjog.2025.03.002","article-title":"The new hope to manage women with mismatch repair proficient endometrial cancer","volume":"64","author":"Wang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.11.019_bib46","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.tjog.2025.07.017","article-title":"Using formalin-fixed paraffin-embedded samples to perform molecular classification of endometrial cancers","volume":"64","author":"Wang","year":"2025","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.11.019_bib47","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jama.2025.9495","article-title":"Ovarian cancer: a review","volume":"334","author":"Caruso","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.tjog.2025.11.019_bib48","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.tjog.2024.05.022","article-title":"A nomogram to predict platinum-sensitivity and survival outcome in women with advanced epithelial ovarian cancer","volume":"63","author":"Yeh","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.11.019_bib49","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.tjog.2024.05.006","article-title":"Evolving treatment paradigms for platinum-resistant ovarian cancer: an update narrative review","volume":"63","author":"Lin","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.11.019_bib50","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.tjog.2021.07.003","article-title":"Treatment for recurrent epithelial ovarian cancer","volume":"60","author":"Li","year":"2021","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.11.019_bib51","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.tjog.2024.09.006","article-title":"Antibody-drug conjugates (ADCs) may be a big breakthrough in gynecologic cancer treatment (II): anti-HER2\/neu","volume":"63","author":"Wang","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2025.11.019_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101978","article-title":"Antibody-drug conjugates in gynecologic cancer: current landscape, clinical data, and emerging targets","volume":"35","author":"He","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.tjog.2025.11.019_bib54","first-page":"34","article-title":"The next frontier in antibody-drug conjugates: challenges and opportunities in cancer and autoimmune therapy","volume":"8","author":"Zhou","year":"2025","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.tjog.2025.11.019_bib55","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3390\/pharmaceutics13101705","article-title":"Antibody-antineoplastic conjugates in gynecological malignancies: current status and future perspectives","volume":"13","author":"Mart\u00edn-Sabroso","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.tjog.2025.11.019_bib56","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.3390\/ijms26115222","article-title":"Folate receptor alpha in advanced epithelial ovarian cancer: diagnostic role and therapeutic implications of a clinically validated biomarker","volume":"26","author":"Zannoni","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.tjog.2025.11.019_bib57","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s12672-025-03933-x","article-title":"The efficacy and safety of mirvetuximab soravtansine for the treatment of recurrent ovarian cancer: an update systematic review and meta-analysis","volume":"16","author":"Dai","year":"2025","journal-title":"Discov Oncol"},{"issue":"3","key":"10.1016\/j.tjog.2025.11.019_bib58","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-473114","article-title":"State of the art: therapies now and around the corner for gynecologic cancers","volume":"45","author":"Moore","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.tjog.2025.11.019_bib59","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1470-2045(25)00021-X","article-title":"Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor \u03b1-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial","volume":"26","author":"Van Gorp","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tjog.2025.11.019_bib60","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Gynecologic oncology group partners and the European network of gynaecological oncological trial groups. Mirvetuximab soravtansine in FR\u03b1-Positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2025.11.019_bib61","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ygyno.2024.10.013","article-title":"Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: an integrated safety summary","volume":"191","author":"Moore","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2025.11.019_bib63","article-title":"Practical clinical management of ocular adverse events related to antibody-drug conjugates in gynaecological malignancies","volume":"134","author":"Bouguerra","year":"2025","journal-title":"Cancer Treat Rev"}],"container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455925003389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455925003389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:15:36Z","timestamp":1778580936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1028455925003389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1028455925003389"],"URL":"https:\/\/doi.org\/10.1016\/j.tjog.2025.11.019","relation":{},"ISSN":["1028-4559"],"issn-type":[{"value":"1028-4559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mirvetuximab soravtansine-Gynx (MIRV) for treating platinum-resistant recurrent ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Taiwanese Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjog.2025.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}